Table 3.
Clinical Characteristics of ICI Therapy for FLC patients.
| Variable | Classification | N (%) |
|---|---|---|
| Immune Checkpoint Inhibitor | Nivolumab monotherapy | 9 (47.4%) |
| Nivolumab + 5FU + IFN | 1 (5.9%) | |
| Nivolumab + regorafenib | 1 (5.9%) | |
| Nivolumab + gemcitabine-based chemotherapy | 1 (5.9%) | |
| Nivolumab + ipilimumab | 2 (11.8%) | |
| Pembrolizumab monotherapy | 4 (23.5%) | |
| Atezolizumab + bevacizumab | 1 (5.3%) | |
| Time on Therapy (months) | Median = 5.1 (range 0–36.5) |
|
| Any ICI Regimen | Progressive Disease | 12 (63.2%) |
| Stable Disease | 4 (21.1%) | |
| Partial Response | 3 (15.8%) | |
| Complete Response | 0 (0%) | |
| ICI Alone Subset (i.e., anti-PD1 +/− CTLA4) |
Progressive Disease | 10 (66.7%) |
| Stable Disease | 3 (20%) | |
| Partial Response | 2 (13.3%) | |
| Complete Response | 0 (0%) |